$5.83
-0.01-0.17%
Last update: 7:17 AM
15 minutes delayed
Comments
Loading...
Definitive Healthcare
DHNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Definitive Healthcare (NASDAQ:DH) Stock, Analyst Ratings, Price Targets, Forecasts
Definitive Healthcare Corp has a consensus price target of $13.35 based on the ratings of 16 analysts. The high is $36 issued by Jefferies on December 2, 2021. The low is $7 issued by Deutsche Bank on May 9, 2024. The 3 most-recent analyst ratings were released by Deutsche Bank, Barclays, and Canaccord Genuity on May 9, 2024, May 9, 2024, and May 8, 2024, respectively. With an average price target of $7.33 between Deutsche Bank, Barclays, and Canaccord Genuity, there's an implied 21.61% upside for Definitive Healthcare Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Deutsche Bank
Barclays
Canaccord Genuity
Stifel
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for Definitive Healthcare
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/09/2024 | Buy Now | 16.09% | Deutsche Bank | George Hill | $10 → $7 | Maintains | Hold | Get Alert |
| 05/09/2024 | Buy Now | 16.09% | Barclays | Saket Kalia | $11 → $7 | Maintains | Equal-Weight | Get Alert |
| 05/08/2024 | Buy Now | 32.67% | Canaccord Genuity | David Hynes | $10 → $8 | Maintains | Hold | Get Alert |
| 05/08/2024 | Buy Now | 57.55% | Stifel | David Grossman | $11 → $9.5 | Maintains | Buy | Get Alert |
| 05/08/2024 | Buy Now | — | Needham | Ryan MacDonald | — | Reiterates | → Hold | Get Alert |
| 05/08/2024 | Buy Now | 49.25% | Morgan Stanley | Craig Hettenbach | $11.5 → $9 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 03/01/2024 | Buy Now | 82.42% | Barclays | Saket Kalia | $10 → $11 | Maintains | Equal-Weight | Get Alert |
| 02/29/2024 | Buy Now | 65.84% | Canaccord Genuity | David Hayes | $9 → $10 | Maintains | Hold | Get Alert |
| 01/17/2024 | Buy Now | 82.42% | Stifel | David Grossman | $12 → $11 | Maintains | Buy | Get Alert |
| 01/17/2024 | Buy Now | — | Needham | Ryan MacDonald | — | Downgrade | Buy → Hold | Get Alert |
| 01/05/2024 | Buy Now | 65.84% | Canaccord Genuity | David Hayes | → $10 | Downgrade | Buy → Hold | Get Alert |
| 11/03/2023 | Buy Now | 57.55% | Morgan Stanley | Craig Hettenbach | $15.5 → $9.5 | Maintains | Overweight | Get Alert |
| 08/16/2023 | Buy Now | 74.13% | Goldman Sachs | Kash Rangan | $17 → $10.5 | Maintains | Neutral | Get Alert |
| 08/15/2023 | Buy Now | 99% | Canaccord Genuity | David Hayes | $13 → $12 | Maintains | Buy | Get Alert |
| 08/15/2023 | Buy Now | 148.76% | Morgan Stanley | Craig Hettenbach | $17 → $15 | Maintains | Overweight | Get Alert |
| 08/15/2023 | Buy Now | 74.13% | B of A Securities | Allen Lutz | $12 → $10.5 | Maintains | Neutral | Get Alert |
| 08/15/2023 | Buy Now | 148.76% | Needham | Ryan MacDonald | → $15 | Reiterates | Buy → Buy | Get Alert |
| 08/01/2023 | Buy Now | 148.76% | Needham | Ryan MacDonald | → $15 | Reiterates | Buy → Buy | Get Alert |
| 07/24/2023 | Buy Now | 115.59% | Baird | Vikram Kesavabhotla | → $13 | Downgrade | Outperform → Neutral | Get Alert |
| 06/16/2023 | Buy Now | 148.76% | Needham | Ryan MacDonald | → $15 | Reiterates | → Buy | Get Alert |
| 05/08/2023 | Buy Now | 65.84% | Barclays | Saket Kalia | $11 → $10 | Maintains | Equal-Weight | Get Alert |
| 05/05/2023 | Buy Now | 82.42% | B of A Securities | Allen Lutz | → $11 | Maintains | Neutral | Get Alert |
| 05/05/2023 | Buy Now | 99% | Credit Suisse | Jonathan Yong | $15 → $12 | Maintains | Neutral | Get Alert |
| 05/05/2023 | Buy Now | 148.76% | Needham | Ryan MacDonald | → $15 | Reiterates | → Buy | Get Alert |
| 04/19/2023 | Buy Now | — | William Blair | Ryan Daniels | — | Initiates | → Outperform | Get Alert |
| 02/28/2023 | Buy Now | 181.92% | Morgan Stanley | — | $18 → $17 | Maintains | Overweight | Get Alert |
| 02/24/2023 | Buy Now | 148.76% | Credit Suisse | Jonathan Yong | $19 → $15 | Maintains | Neutral | Get Alert |
| 02/24/2023 | Buy Now | 148.76% | Needham | Ryan MacDonald | → $15 | Reiterates | → Buy | Get Alert |
| 01/06/2023 | Buy Now | 198.51% | Morgan Stanley | Craig Hettenbach | $21 → $18 | Maintains | Overweight | Get Alert |
| 11/07/2022 | Buy Now | 181.92% | Goldman Sachs | Kash Rangan | $31 → $17 | Maintains | Neutral | Get Alert |
| 11/04/2022 | Buy Now | 248.26% | Morgan Stanley | Craig Hettenbach | $23 → $21 | Maintains | Overweight | Get Alert |
| 11/04/2022 | Buy Now | 215.09% | Credit Suisse | Jonathan Yong | $24 → $19 | Maintains | Neutral | Get Alert |
| 11/04/2022 | Buy Now | 148.76% | Needham | Ryan MacDonald | $32 → $15 | Maintains | Buy | Get Alert |
| 10/24/2022 | Buy Now | 281.43% | Morgan Stanley | Craig Hettenbach | $34 → $23 | Maintains | Overweight | Get Alert |
| 08/08/2022 | Buy Now | 463.85% | Morgan Stanley | Craig Hettenbach | $37 → $34 | Maintains | Overweight | Get Alert |
| 08/08/2022 | Buy Now | 281.43% | Barclays | Saket Kalia | $24 → $23 | Maintains | Equal-Weight | Get Alert |
| 07/06/2022 | Buy Now | 397.51% | Needham | Ryan MacDonald | → $30 | Initiates | → Buy | Get Alert |
| 05/06/2022 | Buy Now | 513.6% | Morgan Stanley | Craig Hettenbach | $40 → $37 | Maintains | Overweight | Get Alert |
| 04/05/2022 | Buy Now | 331.18% | Deutsche Bank | George Hill | $21 → $26 | Maintains | Hold | Get Alert |
| 02/24/2022 | Buy Now | 298.01% | Credit Suisse | Jailendra Singh | $30 → $24 | Maintains | Neutral | Get Alert |
| 02/24/2022 | Buy Now | 364.34% | Canaccord Genuity | David Hayes | $46 → $28 | Upgrade | Hold → Buy | Get Alert |
| 01/25/2022 | Buy Now | 248.26% | Deutsche Bank | George Hill | $45 → $21 | Maintains | Hold | Get Alert |
| 01/19/2022 | Buy Now | 331.18% | Barclays | Saket Kalia | $47 → $26 | Maintains | Equal-Weight | Get Alert |
| 12/17/2021 | Buy Now | 563.35% | Morgan Stanley | Craig Hettenbach | — | Upgrade | Equal-Weight → Overweight | Get Alert |
| 12/16/2021 | Buy Now | 563.35% | Morgan Stanley | Craig Hettenbach | — | Upgrade | Equal-Weight → Overweight | Get Alert |
| 12/02/2021 | Buy Now | 497.01% | Jefferies | Glen Santangelo | — | Initiates | → Buy | Get Alert |
| 11/17/2021 | Buy Now | 729.19% | Baird | Vikram Kesavabhotla | — | Initiates | → Outperform | Get Alert |
| 10/11/2021 | Buy Now | — | Raymond James | Brian Peterson | — | Initiates | → Market Perform | Get Alert |
| 10/11/2021 | Buy Now | 679.44% | Barclays | Saket Kalia | — | Initiates | → Equal-Weight | Get Alert |
| 10/11/2021 | Buy Now | 729.19% | Credit Suisse | Jailendra Singh | — | Initiates | → Neutral | Get Alert |
| 10/11/2021 | Buy Now | 662.85% | Morgan Stanley | Craig Hettenbach | — | Initiates | → Equal-Weight | Get Alert |
| 10/11/2021 | Buy Now | 463.85% | Goldman Sachs | Kash Rangan | — | Initiates | → Neutral | Get Alert |
FAQ
What is the target price for Definitive Healthcare (DH) stock?
The latest price target for Definitive Healthcare (NASDAQ:DH) was reported by Deutsche Bank on May 9, 2024. The analyst firm set a price target for $7.00 expecting DH to rise to within 12 months (a possible 20.07% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Definitive Healthcare (DH)?
The latest analyst rating for Definitive Healthcare (NASDAQ:DH) was provided by Deutsche Bank, and Definitive Healthcare maintained their hold rating.
When was the last upgrade for Definitive Healthcare (DH)?
The last upgrade for Definitive Healthcare Corp happened on February 24, 2022 when Canaccord Genuity raised their price target to $28. Canaccord Genuity previously had a hold for Definitive Healthcare Corp.
When was the last downgrade for Definitive Healthcare (DH)?
The last downgrade for Definitive Healthcare Corp happened on May 8, 2024 when Morgan Stanley changed their price target from $11.5 to $9 for Definitive Healthcare Corp.
When is the next analyst rating going to be posted or updated for Definitive Healthcare (DH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Definitive Healthcare, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Definitive Healthcare was filed on May 9, 2024 so you should expect the next rating to be made available sometime around May 9, 2025.
Is the Analyst Rating Definitive Healthcare (DH) correct?
While ratings are subjective and will change, the latest Definitive Healthcare (DH) rating was a maintained with a price target of $10.00 to $7.00. The current price Definitive Healthcare (DH) is trading at is $5.83, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.